| Rubicon Research Private Limited Patent applications |
| Patent application number | Title | Published |
|---|
| 20120093738 | TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS - The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations. | 04-19-2012 |
| 20110229569 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT - The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers. | 09-22-2011 |
| 20110177175 | DIETARY FIBER COMPOSITIONS - The present invention relates to dietary fiber compositions comprising fenugreek dietary fibers. The present invention also relates to use of these compositions as dietary supplements, functional foods or pharmaceutical preparations for promoting satiety and weight loss, lowering cholesterol, controlling blood glucose, maintaining colon health and modulating inflammation. | 07-21-2011 |
| 20100215740 | TASTE-MASKED ORALLY DISINTEGRATING TABLETS OF MEMANTINE HYDROCHLORIDE - The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 seconds. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mechanical strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients. | 08-26-2010 |
| 20090123543 | PHARMACEUTICAL COMPOSITIONS - A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacological active ingredient active ingredient belongs to the class of angiotensin receptor blocking agents preferably is valsartan optionally in combination with hydrochlorothiazide. The active ingredient may also be a class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors preferably atorvastatin. The ratio of hydrophobic active ingredient to particle separating agent is about 20:1 to about 1:20. The process for the preparation of the novel solid oral dosage form comprises treating a hydrophobic active ingredient with at least one particle separating agent, and incorporating the treated hydrophobic active ingredient into a solid dosage form. | 05-14-2009 |
| 20090087485 | Orally Disintegrating Tablets - The present invention describes a directly compressible composite excipient prepared by coating calcium silicate with a carbohydrate. The present invention further describes the incorporation of the composite excipient into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity. | 04-02-2009 |
